Medical necessity review / prior authorization

Requests for cardiac event monitoring that do not meet the medical necessity criteria and repeat studies within 1 year of a previous study are subject to medical necessity review; prior authorization may be required per payer process.

• Medical necessity review applies to requests that do not meet policy criteria.
• Repeat studies within 1 year of a previous study are subject to review.

Coverage requires fitting CMS categories or demonstrated improved utility

Medicare coverage is limited to ambulatory cardiac monitoring devices that fit CMS-defined categories (patient/event-activated intermittent or non-activated continuous recorders); documentation demonstrating improved clinical utility may be required for devices outside these categories.

• CMS will not cover devices/services that do not fit established ambulatory monitoring categories.
• Peer-reviewed evidence of improved clinical utility may prompt CMS to create new coverage categories.

Prior authorization for extended-duration monitors

Authorization may be required for longer-duration external or implantable monitors (for example, 30-day external event recorders or insertable cardiac monitors) when used to increase AF detection or for extended-duration monitoring.

• Extended-duration devices (e.g., 30-day recorders, ICMs) are supported by evidence for AF detection after cryptogenic stroke.
• Single-use patch monitors (e.g., Zio AT) provide up to 14 days of monitoring and may have payer-specific authorization requirements.

Prior authorization — device descriptions

Device descriptions in the policy (for example, Zio AT single-use patch providing up to 14 days of monitoring) are informational; specific prior authorization rules are determined by the payer and member's plan.

• Zio AT is a single-use mobile cardiac telemetry monitor that can provide monitoring for up to 14 days.
• Device descriptions do not replace plan-specific prior authorization requirements.

Prior authorization determined by member's plan

Refer to the member's plan and program provisions for final prior authorization and coverage determinations; the Clinical Policy Bulletin is guidance and does not by itself guarantee coverage.

• Coverage and prior authorization requirements are determined by the member's plan.
• Clinical Policy Bulletins are not contracts and do not supersede plan provisions.

Implantable loop recorder escalation

For implantable loop recorders, prior noninvasive ambulatory monitoring (such as 30-day presymptom external loop recordings or MCT) should fail to establish a diagnosis in higher-risk patients before proceeding to implantation; for lower-risk patients, symptoms must be so infrequent (less than once per month) that noninvasive monitoring is unlikely to capture diagnostic ECG.

• Patients with heart failure, prior MI, or significant ECG abnormalities: require failed 30-day external recordings or MCT before ICM.
• Patients without those risk factors: symptoms infrequent (< once/month) may justify ICM without prior long monitoring.

Escalation from short-term to extended monitoring

Escalate from short-term (24–48 hour) Holter or telemetry to longer external or continuous monitoring (for example MCT, extended patch, or ICM) when initial short-duration monitoring is non-diagnostic and symptoms are intermittent or paroxysmal.

• EMBRACE and CRYSTAL AF trials support extended monitoring (30 days or ICM) to increase AF detection after cryptogenic stroke.
• MCT has higher diagnostic yield versus patient-activated loop recorders in patients with prior non-diagnostic 24-hour Holter.

Preferred trial of external monitoring

Try several weeks of external rhythm monitoring (for example, extended patch or 30-day external event recorders) before proceeding to more expensive implantable loop recorders in many patients with cryptogenic stroke or intermittent symptoms.

• Editorial guidance favors external loop recorders (as in EMBRACE) as likely cost-effective first step.
• External 30-day monitoring significantly increases AF detection compared with 24-hour monitoring.

Pacemaker event monitor limitations — consider confirmatory testing

Pacemaker event monitors may under-estimate ventricular arrhythmias compared with ambulatory Holter monitoring; confirmatory testing or standardized programming/algorithms should be used before relying solely on pacemaker event logs for clinical decisions.

• Study of 129 pacemaker patients found low agreement between pacemaker event monitors and Holter for many ventricular arrhythmia parameters.
• Standardization of pacemaker detection algorithms is recommended prior to clinical reliance.

Required coding documentation

Providers must submit coding that corresponds to the selected monitor type (CPT/HCPCS) and include appropriate diagnosis codes listed in the policy when requesting coverage or submitting claims.

• Include CPT/HCPCS codes for the chosen device (e.g., 93228, 93241, 33285, 93268) as listed in the policy code sections.
• Include applicable ICD-10 diagnosis codes (e.g., I47–I49, R55) to support medical necessity.

Required clinical context documentation

Document prior short-duration monitoring and clinical findings: include results of prior non-diagnostic Holter or 24–48 hour telemetry, the clinical indication (e.g., cryptogenic stroke), and any monitoring results used to justify extended or implantable monitoring.

• Document non-diagnostic Holter/48-hour telemetry prior to extended monitoring.
• Provide clinical monitoring results and diagnostic findings (e.g., arrhythmia detection episodes) to support device selection.

Baseline ECG monitoring and indication

Include baseline ECG monitoring and specific indication (for example, prior ≥24 hours of ECG monitoring and cryptogenic stroke) when requesting extended ambulatory or implantable monitoring; randomized trials enrolled patients after at least 24 hours of ECG monitoring.

• State prior short-duration ECG monitoring (≥24 hours) and the indication such as cryptogenic stroke.
• Trials (EMBRACE, CRYSTAL AF) randomized patients after standard short-duration monitoring.

Documentation: clinical indication, high-risk features, prior testing, device details

Documentation should include clinical indication, presence or absence of short-term high-risk syncope features, prior testing (e.g., Holter), and device-specific details (for example, pacemaker event counter programming) when citing monitoring results or requesting coverage.

• Report presence/absence of ESC-defined short-term high-risk criteria (see appendix).
• If citing pacemaker-derived data, include programming settings and consider confirming with Holter if accuracy is uncertain.

Provider responsibility for medical advice and plan-consistent documentation

Treating providers are responsible for medical advice and treatment of members and must submit documentation consistent with plan benefits and program provisions referenced by Aetna; policy bulletins do not replace plan/program provisions.

• Providers must follow member-specific program provisions when submitting documentation or seeking authorization.
• Clinical Policy Bulletins are guidance and do not by themselves constitute coverage.

Denial triggers — insufficient documentation or unmet criteria

Claims may be denied if documentation does not support medical necessity per plan provisions or participating provider rules—ensure submitted records clearly justify the selected monitor type and meet policy criteria.

• Requests not meeting medical necessity criteria or lacking supporting documentation are subject to denial.
• Repeat studies within one year without justification may be denied.

Medicare category-based coverage constraint

CMS excludes ambulatory cardiac monitoring devices or services that do not fit the agency's established categories (patient/event-activated intermittent or non-activated continuous recorders); use of devices outside these categories may be non-covered unless peer-reviewed evidence shows improved clinical utility.

• Devices must fit CMS categories to be eligible for Medicare coverage.
• Publication of peer-reviewed evidence showing superior clinical utility may prompt CMS to consider coverage.

Pacemaker event recorder limitations — risk of under-estimation

Pacemaker event monitors can under-estimate ventricular arrhythmias compared with Holter monitoring; relying solely on pacemaker event logs without confirmatory testing or standardized algorithms could lead to inaccurate assessment and potential coverage challenges.

• Study showed low agreement between pacemaker event monitors and Holter for many VA parameters.
• Standardization or confirmatory Holter testing is recommended before clinical reliance.

Short-term high-risk criteria — hospitalize rather than outpatient monitoring

Presence of any short-term high-risk criteria (for example, severe structural heart disease, syncope with exertion, family history of sudden cardiac death, non-sustained VT, conduction abnormalities with QRS ≥120 ms, prolonged/short QT, Brugada pattern, ARVC features, severe anemia, or electrolyte disturbance) warrants prompt hospitalization or intensive evaluation and may preclude outpatient/event monitoring.

• Patients meeting ESC short-term high-risk criteria should not be managed with outpatient event monitoring until stabilized.
• Attempting outpatient monitoring instead of hospitalization in high-risk patients may lead to denial.